Paradigm Biocapital Advisors LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001855655

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2024 · 35 positions · Total reported value $2.61B · Top-10 concentration 64.6% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 54.3% · 7 new · 6 cut · 6 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q2 2024 13F filing, Paradigm Biocapital Advisors LP disclosed 35 equity positions with a combined reported value of $2.61B. The filing implies a focused portfolio: its ten largest positions account for 64.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2024 were NUVL ($346.81M), ARGX ($231.42M), ACLX ($212.38M). By sector, the heaviest allocations are Health Care 63.4%, Other 36.6%. Versus the prior quarter, allocation shifted toward Other (+2.5pp) and away from Health Care (-2.5pp).

Versus the prior quarter, Paradigm Biocapital Advisors LP opened 7 new positions, trimmed 6 and fully exited 6, a turnover rate of 54.3% of positions. The portfolio's overlap with the prior quarter was 57% of names.

The largest new positions opened in Q2 2024 were MRUS ($119.51M), JANX ($65.53M), COGT ($30.55M).

Of the 6 positions fully exited versus the prior quarter, the largest were IMCR ($116.17M), ALPN ($84.08M), BCYC ($80.84M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2024)

  • MRUS MERUS N V · $119.51M
  • JANX JANUX THERAPEUTICS INC · $65.53M
  • COGT COGENT BIOSCIENCES INC · $30.55M
  • BBIO BRIDGEBIO PHARMA INC · $27.60M
  • ERAS ERASCA INC · $17.11M
  • VRNA VERONA PHARMA PLC · $10.43M
  • ALXO ALX ONCOLOGY HLDGS INC · $9.50M
  • CATX PERSPECTIVE THERAPEUTICS INC · $9.17M

Fully Exited (vs previous quarter)

  • IMCR IMMUNOCORE HLDGS PLC · prev qtr: $116.17M
  • ALPN ALPINE IMMUNE SCIENCES INC · prev qtr: $84.08M
  • BCYC BICYCLE THERAPEUTICS PLC · prev qtr: $80.84M
  • AUTL AUTOLUS THERAPEUTICS LTD · prev qtr: $41.00M
  • ZNTL ZENTALIS PHARMACEUTICALS INC · prev qtr: $14.89M
  • AGIO AGIOS PHARMACEUTICALS INC · prev qtr: $11.70M
  • CRBU CARIBOU BIOSCIENCES INC · prev qtr: $11.17M
  • CRGX CARGO THERAPEUTICS INC · prev qtr: $3.30M

Insider Transactions (Form 4)

Latest Paradigm Biocapital Advisors LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Paradigm Biocapital Advisors LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 28 positions worth $5.34B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-120338 (status: Approved), registered 2021-02-23
  • Regulatory AUM (Form ADV): $4.47B as of 2026-08-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds

Portfolio Structure

  • 28 positions · $5.34B reported value (Q2 2026)
  • Top 10 holdings = 75.2% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 22.3%
  • Average position size: $190.73M

Sector Tilt

  • Health Care 81.2%
  • Industrials 0.8%
  • (classified holdings cover 82% of value)

Quarterly Activity

  • Q2 2026: 7 new, 12 added, 7 reduced, 14 exited
  • 2 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 63.4%
Other 36.6%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 4.57M $346.81M 13.27%
13.27%
Add
2 538.14K $231.42M 8.86%
8.86%
Reduce
3 3.85M $212.38M 8.13%
8.13%
Add
4 5.26M $204.11M 7.81%
7.81%
Add
5 947.57K $149.72M 5.73%
5.73%
Reduce
6 2.70M $121.90M 4.67%
4.67%
Add
7 2.02M $119.51M 4.57%
4.57%
New
8 2.51M $112.57M 4.31%
4.31%
Reduce
9 2.33M $95.29M 3.65%
3.65%
Hold
10 4.54M $93.47M 3.58%
3.58%
Add
11 664.31K $90.60M 3.47%
3.47%
Add
12 7.90M $85.52M 3.27%
3.27%
Hold
13 2.04M $79.67M 3.05%
3.05%
Reduce
14 2.44M $66.19M 2.53%
2.53%
Reduce
15 1.56M $65.53M 2.51%
2.51%
New
16 2.44M $64.90M 2.48%
2.48%
Reduce
17 1.20M $53.29M 2.04%
2.04%
Reduce
18 627.20K $47.36M 1.81%
1.81%
Reduce
19 3.87M $46.76M 1.79%
1.79%
Add
20 2.33M $41.88M 1.60%
1.60%
Reduce
21 3.42M $39.76M 1.52%
1.52%
Add
22 2.90M $37.68M 1.44%
1.44%
Reduce
23 1.36M $35.98M 1.38%
1.38%
Add
24 3.62M $30.55M 1.17%
1.17%
New
25 1.09M $27.60M 1.06%
1.06%
New
26 1.54M $26.91M 1.03%
1.03%
Add
27 7.25M $17.11M 0.66%
0.66%
New
28 2.34M $14.11M 0.54%
0.54%
Reduce
29 330.00K $12.99M 0.50%
0.50%
Hold
30 721.09K $10.43M 0.40%
0.40%
New
31 1.58M $9.50M 0.36%
0.36%
New
32 919.69K $9.17M 0.35%
0.35%
New
33 6.46M $6.46M 0.25%
0.25%
Hold
34 659.72K $3.83M 0.15%
0.15%
New
35 353.89K $2.07M 0.08%
0.08%
New

FAQ

What did Paradigm Biocapital Advisors LP buy in 2024-Q2?

In its 2024-Q2 13F filing, Paradigm Biocapital Advisors LP reported 35 equity positions worth $2.61B in aggregate; its largest disclosed positions were NUVL ($346.81M), ARGX ($231.42M), ACLX ($212.38M).

How large is Paradigm Biocapital Advisors LP's portfolio?

Paradigm Biocapital Advisors LP reported $2.61B of long equity holdings across 35 positions as of 2024-Q2. Top-10 holdings account for 64.6% of reported value.

What is Paradigm Biocapital Advisors LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/paradigm-biocapital-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →